BackOruka Therapeutics Overview
Oruka Therapeutics, Inc.

Oruka Therapeutics Target Price

Analysts' average 12-month price target for Oruka Therapeutics is $140.

Get informed when a big investor buys or sells

+ Follow

Share Price

$94.96

Average Target Price

$143.3350.9% upside

3 analysts in the last 4 months

High: $180 | Low: $120

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-03Mizuho Securities$12026.4% upsideOpen
2026-07-01UBS$13036.9% upsideOpen
2026-06-02Piper SandlerYasmeen Rahimi$18089.6% upsideOpen
2026-04-30Leerink Partners$12026.4% upsideOpen
2026-04-29H.C. Wainwright$12026.4% upsideOpen
2026-04-28UBS$1005.3% upsideOpen
2026-04-27Wedbush$16573.8% upsideOpen
2026-04-27BarclaysEtzer Darout$16068.5% upsideOpen
2026-04-27Guggenheim$200110.6% upsideOpen
2026-04-27BTIG$15159% upsideOpen
2026-04-15Wedbush$8510.5% downsideOpen
2026-03-13BTIGJulian Harrison$7323.1% downsideOpen
2026-01-13Wedbush$4552.6% downsideOpen
2026-01-07UBSMichael Yee$5047.3% downsideOpen
2025-12-18Piper Sandler$7521% downsideOpen
2025-10-27Guggenheim$6036.8% downsideOpen
2025-10-27H.C. WainwrightMitchell Kapoor$4057.9% downsideOpen
2025-10-13Barclays$4849.5% downsideOpen
2025-02-04Wolfe ResearchAndy Chen$2078.9% downsideOpen
2024-09-12JefferiesMichael Yee$4057.9% downsideOpen
2024-09-04WedbushDavid Nierengarten$4057.9% downsideOpen

Oruka Therapeutics (ORKA) FAQ

Oruka Therapeutics posts a target price of $140. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $140 for ORKA means covering analysts, on average, see the stock 50.9% upside of $94.96 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ORKA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Oruka Therapeutics's other metric pages and overview cover the third.

Judging Oruka Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $140 here, then scan peer and history charts to see if the gap is persistent.